Lyell Immunopharma, Inc.
LYEL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001806952
In the last 90 days, Lyell Immunopharma, Inc. insiders filed 0 open-market purchases and 10 sales; 87 institutions reported holding it in 13F filings for Q2 2026, worth $178.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Lyell Immunopharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 10 filings
- 6 insiders, $211.3K in total
- Insiders trading
- 6
- Net value
- −$211.3K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Lyell Immunopharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Shook David | Chief Medical Officer | 20,423 | Sep 10, 2026 | 3 |
| Aguirre Jarrad Mattieu | Chief Medical Officer | – | Sep 10, 2026 | 1 |
| Seely Lynn | President and CEO | 63,899 | Aug 25, 2026 | 7 |
| Hill Stephen J. | Chief Operating Officer | 16,816 | Aug 25, 2026 | 7 |
| Lee Gary K. | Chief Scientific Officer | 16,220 | Aug 25, 2026 | 7 |
| Bulis Veronica Sanchez | VP, Corporate Controller | 14,799 | Aug 11, 2026 | 5 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | 2,774,980 | Jul 27, 2026 | 6 |
| Rieflin William JL | Director | – | Jun 12, 2026 | 1 |
| Brawley Otis W | Director | 35,640 | Jun 12, 2026 | 1 |
| Friedman Cathy | Director | 236,370Indirect | Jun 12, 2026 | 1 |
| Ramachandra Sumant | Director | 200,000Indirect | Jun 12, 2026 | 1 |
| Klausner Richard | Director | 843,365Indirect | Jun 12, 2026 | 1 |
| Nabel Elizabeth G | Director | – | Jun 12, 2026 | 1 |
| Bachleda Mark | Director | – | Jun 12, 2026 | 1 |
| Shah Smital | Chief Fin. and Bus. Officer | – | Mar 16, 2026 | 1 |
| ARCH Venture Fund IX, L.P. | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| ARCH Venture Fund IX Overage, L.P. | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| ARCH Venture Partners IX Overage, L.P. | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| ARCH Venture Partners IX, L.P. | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| ARCH Venture Partners IX, LLC | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| Berns Paul L | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| Crandell Keith | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| Nelsen Robert | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| Bybee Clinton | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| Gillis Steven | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| Burow Kristina | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| ARCH Venture Fund XIII, L.P. | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| ARCH Venture Partners XIII, LLC | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| ARCH Venture Partners XIII, L.P. | 10% Owner | 1,426,528Indirect | Mar 9, 2026 | 1 |
| Meltz Mark A | General Counsel | – | Feb 11, 2026 | 1 |
| Newton Charles W. | Chief Financial Officer | 15,306 | Aug 22, 2025 | 0 |
| Lang Matthew | Chief Business Officer | 162,500 | Feb 26, 2025 | 0 |
| Bishop Hans Edgar | Director | 4,685,614 | Jun 17, 2024 | 0 |
| Thompson Rahsaan | Chief Legal Officer | – | Feb 28, 2023 | 0 |
| Albertson Tina M. | Chief Medical Officer | – | Feb 28, 2023 | 0 |
| Turner Heather D | Chief General Counsel | – | Mar 18, 2022 | 0 |
| Homans Elizabeth | Chief Executive Officer | – | Mar 18, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 (view filing)7:37 PM ET | Sep 10 | Same day | Shook DavidChief Medical Officer | SSale | −500 | $12.70 | −$6.35K | −2.4%20.4K after | |
| Aug 25, 2026 (view filing)4:06 PM ET | Aug 21 | 4 days | Seely LynnPresident and CEO | SSale | −9.59K | $15.54 | −$149.0K | −13.0%63.9K after | |
| Aug 25, 2026 (view filing)4:05 PM ET | Aug 21 | 4 days | Hill Stephen J.Chief Operating Officer | SSale | −989 | $15.54 | −$15.4K | −5.6%16.8K after | |
| Aug 25, 2026 (view filing)4:03 PM ET | Aug 21 | 4 days | Lee Gary K.Chief Scientific Officer | SSale | −1.46K | $15.54 | −$22.6K | −8.2%16.2K after | |
| Aug 11, 2026 (view filing)4:21 PM ET | Aug 10 | 1 day | Bulis Veronica SanchezVP, Corporate Controller | SSale | −621 | $14.34 | −$8.91K | −4.0%14.8K after | |
| Aug 11, 2026 (view filing)4:20 PM ET | Aug 10 | 1 day | Lee Gary K.Chief Scientific Officer | SSale | −131 | $14.34 | −$1.88K | −0.7%17.7K after | |
| Aug 11, 2026 (view filing)4:18 PM ET | Aug 10 | 1 day | Hill Stephen J.Chief Operating Officer | SSale | −89 | $14.34 | −$1.28K | −0.5%17.8K after | |
| Aug 11, 2026 (view filing)4:07 PM ET | Aug 10 | 1 day | Seely LynnPresident and CEO | SSale | −390 | $14.34 | −$5.59K | −0.5%73.5K after | |
| Jul 20, 2026 (view filing)2:55 PM ET | Jul 17 | 3 days | Innovative Cellular Therapeutics Holdings Ltd10% Owner | SSale | −10 | $13.70 | −$137 | 0.0%2.86M after | 10b5-1 |
| Jul 17, 2026 (view filing)9:45 PM ET | Jul 16 | 1 day | Innovative Cellular Therapeutics Holdings Ltd10% Owner | SSale | −10 | $13.73 | −$137.3 | 0.0%2.86M after | 10b5-1 |
| Jun 15, 2026 (view filing) | May 11 | 35 daysLate | Bulis Veronica SanchezVP, Corporate Controller | SSale | −217 | $18.91 | −$4.10K | −1.4%15.4K after | |
| Jun 15, 2026 (view filing) | May 11 | 35 daysLate | Lee Gary K.Chief Scientific Officer | SSale | −130 | $18.92 | −$2.46K | −0.7%17.8K after | |
| Jun 15, 2026 (view filing) | May 11 | 35 daysLate | Hill Stephen J.Chief Operating Officer | SSale | −89 | $18.92 | −$1.68K | −0.5%17.9K after | |
| Jun 15, 2026 (view filing) | May 11 | 35 daysLate | Seely LynnPresident and CEO | SSale | −388 | $18.91 | −$7.34K | −0.5%73.9K after | |
| Jun 11, 2026 (view filing) | Jun 10 | 1 day | Shook DavidChief Medical Officer | SSale | −1.98K | $12.64 | −$25.0K | −8.6%20.9K after | |
| Mar 9, 2026 (view filing)4:36 PM ET | Mar 6 | 3 days | ARCH Venture Fund IX, L.P. and 4 others10% Owner | PPurchase | +488.1K | $25.61 | +$12.5M | +52.0%1.43M after | Duplicate filing |
| Mar 9, 2026 (view filing)4:34 PM ET | Mar 6 | 3 days | Berns Paul L and 8 others10% Owner | PPurchase | +488.1K | $25.61 | +$12.5M | +52.0%1.43M after | |
| Feb 12, 2026 (view filing) | Feb 11 | 1 day | Lee Gary K.Chief Scientific Officer | SSale | −1.67K | $23.39 | −$39.1K | −9.0%16.9K after | |
| Feb 12, 2026 (view filing) | Feb 11 | 1 day | Hill Stephen J.Chief Operating Officer | SSale | −1.24K | $23.39 | −$28.9K | −6.5%17.8K after | |
| Feb 12, 2026 (view filing) | Feb 11 | 1 day | Seely LynnPresident and CEO | SSale | −7.46K | $23.39 | −$174.4K | −9.1%74.3K after | |
| Feb 11, 2026 (view filing) | Feb 10 | 1 day | Bulis Veronica SanchezVP, Corporate Controller | SSale | −254 | $23.12 | −$5.87K | −1.6%15.6K after | |
| Feb 11, 2026 (view filing) | Feb 10 | 1 day | Lee Gary K.Chief Scientific Officer | SSale | −147 | $23.12 | −$3.40K | −0.8%18.6K after | |
| Feb 11, 2026 (view filing) | Feb 10 | 1 day | Hill Stephen J.Chief Operating Officer | SSale | −109 | $23.12 | −$2.52K | −0.6%19.0K after | |
| Feb 11, 2026 (view filing) | Feb 10 | 1 day | Seely LynnPresident and CEO | SSale | −438 | $23.12 | −$10.1K | −0.5%81.7K after | |
| Jan 6, 2026 (view filing) | Dec 24-30, 2025 | 13 daysLate | Bulis Veronica SanchezVP, Corporate Controller | SSale | −2.07K | $35.80 | −$74.2K | −22.5%7.14K after | 2 lots |
| Nov 12, 2025 (view filing) | Nov 10 | 2 days | Bulis Veronica SanchezVP, Corporate Controller | SSale | −239 | $16.10 | −$3.85K | −2.5%9.21K after | |
| Nov 12, 2025 (view filing) | Nov 10 | 2 days | Lee Gary K.Chief Scientific Officer | SSale | −138 | $16.16 | −$2.23K | −0.9%15.4K after | |
| Nov 12, 2025 (view filing) | Nov 10 | 2 days | Hill Stephen J.Chief Operating Officer | SSale | −95 | $16.12 | −$1.53K | −0.6%15.8K after | |
| Nov 12, 2025 (view filing) | Nov 10 | 2 days | Seely LynnPresident and CEO | SSale | −412 | $16.11 | −$6.64K | −0.6%67.2K after | |
| Aug 22, 2025 (view filing) | Aug 21 | 1 day | Seely LynnPresident and CEO | SSale | −7.26K | $10.54 | −$76.5K | −9.7%67.6K after | |
| Aug 22, 2025 (view filing) | Aug 21 | 1 day | Hill Stephen J.Chief Operating Officer | SSale | −1.00K | $10.54 | −$10.6K | −6.0%15.8K after | |
| Aug 22, 2025 (view filing) | Aug 21 | 1 day | Newton Charles W.Chief Financial Officer | SSale | −1.45K | $10.54 | −$15.3K | −8.7%15.3K after | |
| Aug 22, 2025 (view filing) | Aug 21 | 1 day | Lee Gary K.Chief Scientific Officer | SSale | −1.45K | $10.54 | −$15.3K | −8.6%15.5K after | |
| Aug 13, 2025 (view filing) | Aug 11-12 | 2 days | Seely LynnPresident and CEO | SSale | −797 | $10.43 | −$8.32K | −2.2%34.8K after | 2 lots |
| Aug 13, 2025 (view filing) | Aug 11-12 | 2 days | Hill Stephen J.Chief Operating Officer | SSale | −185 | $10.43 | −$1.93K | −2.0%8.85K after | 2 lots |
| Aug 13, 2025 (view filing) | Aug 11-12 | 2 days | Lee Gary K.Chief Scientific Officer | SSale | −267 | $10.43 | −$2.79K | −2.9%8.96K after | 2 lots |
| Aug 13, 2025 (view filing) | Aug 11-12 | 2 days | Newton Charles W.Chief Financial Officer | SSale | −267 | $10.43 | −$2.79K | −3.0%8.76K after | 2 lots |
| Apr 2, 2025 (view filing) | Mar 31 | 2 days | Brawley Otis WDirector | PPurchase | +35.6K | $0.56 | +$20.0K | New position35.6K after | |
| Mar 25, 2025 (view filing) | Mar 21 | 4 days | Ramachandra SumantDirector | PPurchase | +200.0K | $0.58 | +$116.0K | New position200.0K after | |
| Mar 18, 2025 (view filing) | Mar 14 | 4 days | Klausner RichardDirector | PPurchase | +158.0K | $0.60 | +$94.8K | +23.1%843.4K after | |
| Mar 18, 2025 (view filing) | Mar 17 | 1 day | Newton Charles W.Chief Financial Officer | PPurchase | +200.0K | $0.56 | +$112.0K | New position200.0K after | |
| Mar 18, 2025 (view filing) | Mar 14 | 4 days | Seely LynnPresident and CEO | PPurchase | +175.0K | $0.61 | +$106.8K | +32.6%712.5K after | |
| Aug 17, 2023 (view filing) | Aug 15 | 2 days | Klausner RichardDirector | SSale | −58.0K | $2.28 | −$132.3K | −5.9%930.9K after | |
| Sep 27, 2022 (view filing) | Sep 23 | 4 days | Klausner RichardDirector | SSale | −11.1K | $6.40 | −$71.0K | −1.1%988.9K after |